Re: Beta-blockers are no longer indicated as first line treatment for vasovagal syncope. This is based on 1 adequately powered, randomized placebo-controlled trial and 4 smaller studies.		
Q1.What is the impact of this e-Therapeutics Highlight on you or you	r practi	ice? Check Yes or No for each item.
	Yes	No
My practice is (will be) changed and improved	0	<b>⊙</b>
I learned something new	•	0
I am motivated to learn more	0	•
This information confirmed I did (am doing) the right thing	0	•
I am reassured	0	•
I am reminded of something I already knew	0	•
I am dissatisfied	0	•
There is a problem with this information	0	•
I disagree with the content of this information	0	•
This information is potentially harmful	0	•
Q2. Is this 'e-Therapeutics Highlight' relevant for at least one of you  O Totally relevant		
Partially relevant		
O Not relevant		
Q3. Will you apply this e-Therapeutics Highlight to at least one patier	it? 💿 '	Yes O No
If YES, how you will apply it? Check Yes or No for each item.		
		Yes No
To better understand a particular issue related to this patient		○ •
To justify or maintain the management of this patient		○ •
To modify the management of this patient		• •
To persuade other health professionals or patients to make change	s	○ ●
Q4. Do you expect any health benefits from applying this e-Therapeu	tics Hig	ghlight to a particular patient?

If YES, what are these benefits? Check Yes or No for each item.

Yes No
Increasing patient knowledge about health or healthcare

Avoiding unnecessary or inappropriate treatment, diagnostic procedure or preventive intervention

Increasing patient acceptability of treatment, diagnostic procedure or preventive intervention

Preventing disease or health deterioration (including acute episode of chronic disease)

Improving patient health or functioning or resilience (i.e., how well the patient faces difficulties)